Novel Biomarkers and Therapeutic Targets for Melanoma

Noa Sabag; Alexander Yakobson; Meir Retchkiman; Eldad Silberstein

doi:10.3390/ijms231911656

Novel Biomarkers and Therapeutic Targets for Melanoma

Noa Sabag, Alexander Yakobson, Meir Retchkiman, Eldad Silberstein

Research output: Contribution to journal › Review article › peer-review

8 Scopus citations

Abstract

Malignant melanoma is one of the most common cancers in the world. In the disease’s early stages, treatment involves surgery, in advanced stages however, treatment options were once scarce. There has been a paradigm shift in advanced melanoma treatment with the introduction of immunotherapy and targeted therapies. Understanding the molecular pathways and their pathologic counterparts helped identifying specific biomarkers that lead to the development of specific targeted therapies. In this review we briefly present some of these markers and their relevance to melanoma treatment.

Original language	English
Article number	11656
Journal	International Journal of Molecular Sciences
Volume	23
Issue number	19
DOIs	https://doi.org/10.3390/ijms231911656
State	Published - 1 Oct 2022

Keywords

adjuvant therapy
immunotherapy
malignant melanoma
targeted therapy

ASJC Scopus subject areas

Catalysis
Molecular Biology
Spectroscopy
Computer Science Applications
Physical and Theoretical Chemistry
Organic Chemistry
Inorganic Chemistry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/ijms231911656

Cite this

@article{719498695702423eb68ca1e2dc13ea09,

title = "Novel Biomarkers and Therapeutic Targets for Melanoma",

abstract = "Malignant melanoma is one of the most common cancers in the world. In the disease{\textquoteright}s early stages, treatment involves surgery, in advanced stages however, treatment options were once scarce. There has been a paradigm shift in advanced melanoma treatment with the introduction of immunotherapy and targeted therapies. Understanding the molecular pathways and their pathologic counterparts helped identifying specific biomarkers that lead to the development of specific targeted therapies. In this review we briefly present some of these markers and their relevance to melanoma treatment.",

keywords = "adjuvant therapy, immunotherapy, malignant melanoma, targeted therapy",

author = "Noa Sabag and Alexander Yakobson and Meir Retchkiman and Eldad Silberstein",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors.",

year = "2022",

month = oct,

day = "1",

doi = "10.3390/ijms231911656",

language = "English",

volume = "23",

journal = "International Journal of Molecular Sciences",

issn = "1661-6596",

publisher = "MDPI Multidisciplinary Digital Publishing Institute",

number = "19",

}

TY - JOUR

T1 - Novel Biomarkers and Therapeutic Targets for Melanoma

AU - Sabag, Noa

AU - Yakobson, Alexander

AU - Retchkiman, Meir

AU - Silberstein, Eldad

PY - 2022/10/1

Y1 - 2022/10/1

N2 - Malignant melanoma is one of the most common cancers in the world. In the disease’s early stages, treatment involves surgery, in advanced stages however, treatment options were once scarce. There has been a paradigm shift in advanced melanoma treatment with the introduction of immunotherapy and targeted therapies. Understanding the molecular pathways and their pathologic counterparts helped identifying specific biomarkers that lead to the development of specific targeted therapies. In this review we briefly present some of these markers and their relevance to melanoma treatment.

AB - Malignant melanoma is one of the most common cancers in the world. In the disease’s early stages, treatment involves surgery, in advanced stages however, treatment options were once scarce. There has been a paradigm shift in advanced melanoma treatment with the introduction of immunotherapy and targeted therapies. Understanding the molecular pathways and their pathologic counterparts helped identifying specific biomarkers that lead to the development of specific targeted therapies. In this review we briefly present some of these markers and their relevance to melanoma treatment.

KW - adjuvant therapy

KW - immunotherapy

KW - malignant melanoma

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85139873514&partnerID=8YFLogxK

U2 - 10.3390/ijms231911656

DO - 10.3390/ijms231911656

M3 - Review article

C2 - 36232957

AN - SCOPUS:85139873514

SN - 1661-6596

VL - 23

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

IS - 19

M1 - 11656

ER -

Novel Biomarkers and Therapeutic Targets for Melanoma

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this